Recent case series describe detection of BK polyomavirus (BKV) in urinary tract cancers in kidney transplant recipients, suggesting that BKV could contribute to the development of these cancers. We assessed risk for urinary tract cancers in kidney recipients with or without treatment for presumed BKV nephropathy (tBKVN) using data from the United States Transplant Cancer Match Study (2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013). Among 55 697 included recipients, 2015 (3.6%) were reported with tBKVN. Relative to the general population, incidence was similarly elevated (approximately 4.5-fold) for kidney cancer in recipients with or without tBKVN, and incidence was not increased in either group for prostate cancer. In contrast, for invasive bladder cancer, incidence was more strongly elevated in recipients with versus without tBKVN (standardized incidence ratios 4.5 vs. 1.7; N = 48 cases), corresponding to an incidence rate ratio (IRR) of 2.9 (95% confidence interval [CI] 1.0-8.2), adjusted for sex, age, transplant year, and use of polyclonal antibody induction. As a result, recipients with tBKVN had borderline increased incidence for all urothelial cancers combined (renal pelvis, ureter, and bladder cancers: adjusted IRR 2.2, 95% CI 0.9-5.4; N = 89 cases). Together with reports describing BKV detection in tumor tissues, these results support an association between BKV and urothelial carcinogenesis among kidney transplant recipients.
acquisition generally occurs in childhood, and the virus is thought to establish a lifelong chronic infection in the epithelium of the urinary tract. Intermittent asymptomatic low-level BK viruria in the range of 10-15% has been reported in immunocompetent individuals, but prospective screening studies suggest that 30-50% of kidney recipients develop BK viruria after transplantation, with a peak incidence in the first 2-12 months. [6] [7] [8] Viruria sometimes progresses to viremia (usually after a gap of a few weeks), with a reported incidence of 5-15%.
Although the progress to viremia closely mirrors the onset of BKVN, the incidence of biopsy-proven BKVN is reported to be only 1-5%, likely due to the focal nature of BKV disease. [9] [10] [11] BKVN often leads to renal allograft loss, and a substantial body of literature exists about this association and its management. 8, 12 Typical treatment regimens for BKVN involve reducing the level of immunosuppressive therapy.
Rarely, BKV has also been associated with hemorrhagic cystitis or ureteral stenosis in kidney recipients. 12 BKV belongs to the polyomavirus family, other members of which have well-known oncogenic effects in rodents. 7, 13 Some members of
Polyomaviridae are associated with cancer in host animals ranging from mice to raccoons. 14 BKV likewise causes various types of cancer, including nephroblastoma, in experimentally challenged rodents. 13 Over the last few years, Merkel cell polyomavirus has been demonstrated to be the causative agent for the majority of Merkel cell carcinomas in humans. 15 Notably, BKV has been linked to aggressive urinary tract cancers in kidney transplant recipients in a large number of recent case reports, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] as summarized by Papadimitriou et al. 35 These reports provide evidence of BKV in the tumors as demonstrated by immunohistochemical staining for BKV proteins, polymerase chain reaction (PCR) testing for BKV DNA, or detection of chromosomally integrated BKV through whole-genome shotgun sequencing of the tumor.
It is important to note that no population-wide studies have investigated the association of BKVN with the risk of developing urinary tract cancers. In this study, we used linked registry data from the United States to perform a detailed comparison of risk for posttransplantation urinary tract cancers among kidney recipients with or without treatment for presumed BKVN.
| METHODS
The study cohort consisted of kidney transplant recipients (includ- We also conducted a sensitivity analysis that considered tBKVN to be present if there was ever an SRTR report of tBKVN, regardless of when it occurred after transplant or in relation to cancer diagnosis.
This approach increased the sensitivity of ascertainment of tBKVN and the number of cancer cases considered to have tBKVN. However, it does not account for duration of time spent following tBKVN, and some tBKVN reports could have occurred after cancer diagnosis.
We also describe selected cancer cases in recipients with tBKVN.
For bladder cancer cases, we report the tumor histology, grade, and stage at diagnosis. For kidney cancers, we describe whether cases arose in the native or donor kidneys based on a review of case documentation by cancer registry staff. Because the transplant was the unit of analysis, people with more than one transplant are included multiple times in the table. The median age at transplantation for recipients with tBKVN was 51 years. For recipients without tBKVN, the median age at transplantation was 49 years. All categories are mutually exclusive and exhaustive, so that sums are all equal to total number of transplantations, except for the reason for transplantation. Because recipients could have more than one reason for transplantation indicated, P values compare the recipients with and without tBKVN separately with respect to each reason.
| RESULTS
Among 55 697 kidney recipients included in this study, 2015 (3.6%)
had an indication of tBKVN in the period 6 months to 2 years posttransplantation ( A total of 584 incident cases of urinary tract cancers (including in situ bladder cancer) were identified in the study cohort (Table 2) .
When compared to the general population, the incidence was similarly elevated for kidney cancer (~4.5-fold) in recipients with or without tBKVN, and the incidence was not increased in either group for prostate cancer. Renal pelvis and ureteral cancers were rare (N = 7 and N = 2 total cases, respectively).
In contrast, for bladder cancer, including both invasive and in situ cases (N = 80), incidence appeared more strongly elevated in recipients with tBKVN than in those without tBKVN (SIRs 2.1 vs. 1.4, Table 2 ). The SIR for invasive bladder cancer, in particular, appeared much higher in the recipients with tBKVN than in those without tBKVN (4.5 vs. 1.7). There were no cases of in situ bladder cancer in the recipients with tBKVN. In Poisson regression models in which all invasive bladder cancer cases were included, recipients with tBKVN had a higher incidence of invasive bladder cancer than those without tBKVN (adjusted IRR, 2.9, 95% CI 1.0-8.2) ( Table 3) . As a result, there was also a borderline increase in incidence for all urothelial cancers as a group (renal pelvis, ureter, and all bladder cancers: adjusted IRR 2.2, 95% CI 0.9-5.4).
The four invasive bladder cancers in recipients with tBKVN were all transitional cell carcinomas. One case described as having undifferentiated grade had spread regionally beyond the bladder at the time of diagnosis. The other cases were diagnosed at localized stage and were described as being well differentiated, poorly differentiated, or of unknown differentiation, respectively. These four cancers were di- tBKVN, treatment for presumed BK polyomavirus nephropathy; CI, confidence interval; SIR, standardized incidence ratio. No other cancer was associated with tBKVN in the sensitivity analysis (data not shown).
| DISCUSSION
BKVN is an important cause of long-term kidney allograft loss. 6, 8, 12 Notably, BKV has also been linked to aggressive urinary tract cancers in kidney transplant recipients in case reports. 35, 36 In our study, we aimed to provide results from a rigorous population-based study to examine the association of tBKVN in kidney recipients with subsequent risk of urinary tract cancers. We report that patients with tBKVN had an almost 3-fold increased incidence for bladder cancers when compared with patients without tBKVN (adjusted IRR 2.9, Table 3 ).
The association with bladder cancer in our study is consistent with that found in previous case reports describing detection of BKV in 12 bladder cancer tumors from kidney transplant recipients. 16, 18, [23] [24] [25] [26] [27] [28] [29] 31 Likewise, a recent single center study found a 12-fold elevated risk of bladder cancer in kidney transplant recipients with evidence of BKVassociated decoy cells in urine, BK viremia, or biopsy-proven BKVN. reports. [38] [39] [40] [41] In our study, the four kidney cancers in recipients with tBKVN for which we had data were all diagnosed in the native kidney. 
29,30
In addition, the viral early genes (in particular, the large tumor antigen We also observed an inverse association between diabetes mellitus and tBKVN, although published findings on the relationship between diabetes and BKVN have been variable. 46, 47 There are also limitations to our study. Because of the relative rarity of tBKVN, the number of cancer cases expected in this group was small, which limited our ability to assess associations with less common cancers. In addition, recipients with tBKVN had relatively short follow-up (mean 2.1 person-years). The four bladder cancers observed in recipients with tBKVN occurred at a median of 4.9 years posttransplantation, and many of the urothelial cancers observed in association with BKV in the literature have occurred later, for example, at a median 5.9 years posttransplantation (range 2-11 years) as summarized by Papadimitriou et al. 35 Thus it is possible that we missed associations of tBKVN with urinary tract malignancies that will become apparent after longer follow-up. Finally, we were unable to capture asymptomatic BK viruria or viremia, so it is possible that we did not capture the full impact of BKV infection relevant for cancer.
To conclude, our results, when taken in conjunction with reports describing BKV detection in tumor tissue, support an etiologic role for BKV in urothelial carcinogenesis, especially with respect to bladder cancer. Our results confirm the rarity of urinary tract cancers, even in patients with tBKVN, but still underscore the need for clinicians to be aware of this association and focus on minimizing development of BKVN with careful prospective monitoring of BKV viremia and appropriate adjustment of immunosuppressive regimens. Finally, our results highlight the importance of ongoing research to understand mechanisms by which BKV could cause cancer and identify risk factors among patients with BKV infection for urinary tract cancers.
